Company: INKT
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0000950170-25-055881
Chunk: 31

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 31
---
| Christine Klaskin                                 |     |                  |     |                  |     |       | — |     | *          |
| Marc van Dijk                                     |     |                  |     |                  |     |       | — |     | *          |
| All current directors and executive officers as a 
 group (9 persons)                                 |     |                  |     |                  |     |       | — |     |            |

* Less than one percent Ownership By Certain Beneficial Owners This table shows certain information, based on filings with the SEC, about the beneficial ownership of our capital stock as of April 24, 2025 by each person known to us owning beneficially more than 5% of any class of our capital stock. Unless otherwise indicated in a footnote to this table, each person has the sole power to invest and vote the shares of common stock listed opposite the person’s name.

| Name and Address of Beneficial Owner |     | Title of 
 Class    |     | Number of Shares |           |     |    |     | Percent of 
 Class      |
| Agenus Inc.                          |     | Common   |     |                  | 2,177,286 |     | -1 |     |            |
| GKCC, LLC                            |     | Common   |     |                  |   464,000 |     | -2 |     |            |

(1) Based on Form 4 filed by Agenus Inc. with the SEC on October 16, 2023. Agenus Inc. The principal business address of the beneficial owner is 3 Forbes Road, Lexington, Massachusetts 02421. (2) Based on Schedule 13G filed by GKCC with the SEC on May 22, 2024. The principal business address of the beneficial owner is 501 Silverside Road, Suite 87AVA, Wilmington, DE 19809.

<div align='center'>23

DELINQUENT SECTION 16(a) REPORTS</div>

Our executive officers, directors, and 10% stockholders are required under Section 16(a) of the 1934 Act, to file reports of ownership and changes in ownership of our securities with the SEC.

Based solely on a review of the copies of reports furnished to us, we believe that during our 2024 fiscal year, all Section 16(a) filing requirements were timely filed other than the reports of ownership and changes in ownership filed related to Dr. Kadlec's Board appointment.

### CERT